OBR Daily Commentary

forumImage

NovaRx Completes Enrollment in Lucanix Pivitol Phase III Therapeutic Vaccine Trial for Post Frontline Maintenace Therapy in Non Small Cell Lung Cancer

(BizJournals) June 20, 2012 - First interim analysis for NSCLC trial in third quarter 2012 - NovaRx Corporation announced that it has recently completed the planned enrollment in its Phase III clinical trial of Lucanix® (belagenpumatucel-L). Lucanix is an investigational whole tumor cell vaccine for the treatment of non-small cell lung cancer.

Read Article arrow

H. Jack West, MD (Posted: June 20, 2012)

quotesWe'll need to see what the results demonstrate, but this is certainly among the most interesting maintenance therapy trials, as well as immunotherapy trials, in lung cancer. Even with the availability of maintenance chemotherapy or erlotinib, there would be a great appeal for an immunotherapy-based treatment with minimal adverse effects. As immunotherapies for cancer gain momentum, a positive trial for belagenpumatucel-L (Lucanix) would be another valuable landmark, and one that could be tested in other lung cancer settings as well. quotes

Add Comment 1 Comment
forumImage

New Therapy Extends Life for Prostate Cancer Patients

(SNM) June 11, 2012 - Prostate cancer patients with advanced tumors that have spread to bone have a poor chance of surviving. Patients with the disease may now live longer with a new line of radioisotope therapy, say researchers at the Society of Nuclear Medicine’s 2012 Annual Meeting.

Read Article arrow

H. Jack West, MD (Posted: June 12, 2012)

quotesRadium-223 is an alpha emitting radioisotope that both significantly improves overall survival (by 3 months) compared with placebo but also reduces skeletal related events in men with metastatic prostate cancer. It also doesn't cause serious problems with irreversible myelosuppression. Once FDA-approved, hopefully later this year, it will be a terrific addition to our armamentarium for prostate cancer, where so many patients have extensive bone metastases and where well-tolerated approaches that significantly prolong survival are in short supply. quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...